Pune, India, September, 2017 /MRFR Press Release/- Market Research Future published a half-cooked research report on Asia Pacific cancer immunotherapy market.
Asia Pacific cancer immunotherapy market is expecting a high growth over the coming future. This is due to increasing number of patient with different types of cancer. Over 100 types of different has been cancer registered, so far. In terms of treatment, limited number of treatments are available in the market. Cancer immunotherapy is expecting to make a huge development over the given period due to its various advantages. Immunotherapy is more effective than other available therapy. The market is majorly driven by increasing cancer population across this region. Increasing smoking population and rising consumption of alcohol have led to increase the number of lungs and liver cancer, which has spurred the growth of the market. However, long time for approval, high cost of treatment, and many side effects may slow the market growth.
In 2016, the Asia Pacific cancer immunotherapy market is expected to grow at a CAGR of 15.5% during the forecasted period.
Asia Pacific cancer immunotherapy market is segmented on the basis of type of therapy, application, and end users. On the basis of type of therapy the market is segmented into monoclonal antibodies, cancer vaccines, immunomodulators, and others. On the basis of application, the market is segmented as lung cancer, blood cancer, melanoma, breast cancer, and other. On the basis of end user, the market is segmented into hospitals & clinics, research laboratories, cancer institute, and others.
Figure 1- Asia Pacific cancer immunotherapy market, by type of therapy
Sources: Annual reports, Press release, White paper, Company Presentation
On the regional basis, Asia Pacific immunotherapy market is dominated by China owing to the presence of huge technological advances, increasing prevalence of cancer, and increasing government support. Beside this developing healthcare sector and increasing expenditure in healthcare have attracted many of the manufacturers to this region. Improvement in healthcare infrastructure, rise in healthcare expenditure and increase in per capita income in countries like India and China have makd this countries as a fastest growing countries in the market.
As no absolute treatments are available for the treatment of cancer many manufacturers are investing in research & development to identify the novel drug against cancer. And this provides a wide range of opportunities for the development of market across the world. Beside this the key challenge for the manufacturers is to provide a cost-effective treatment to the people.
The key players for the market: Amgen, Inc. (US), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), AstraZeneca Plc. (UK), GlaxoSmithKline Plc. (UK), Bayer AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Pfizer, Inc. (US), Merck & Co., Inc. (US), Novartis AG (Switzerland), Spectrum Pharmaceuticals Inc. (US), Janssen Biotech, Inc. (US), Sanofi (France), AbbVie Inc. (US), Takeda Pharmaceuticals (Japan), Oncomed Pharmaceuticals (US), and Immunomedics (US)
Access Complete Report @ https://www.marketresearchfuture.com/reports/asia-pacific-cancer-immunotherapy-market-639